
**eTable 1.** Age-Adjusted Trends in Prescription Drug Use in the Prior 30 Days Among US Adults by Drug Class—1999-2012

**eTable 2.** Results of Joinpoint Trend Analysis for Selected Prescription Drugs

**eTable 3.** Trends in Use of Prescription Drugs in the Prior 30 Days Among US Adults by Age Group—1999-2012

**eTable 4.** Trends in Use of Prescription Drugs in the Prior 30 Days Among US Adults by Sex—1999-2012

**eTable 5.** Trends in Use of Prescription Drugs in the Prior 30 Days Among US Adults by Race/Ethnicity—1999-2012

**eTable 6.** Age-Adjusted Trends in Use of Selected Prescription Drugs in the Prior 30 Days Among US Adults by Race/Ethnicity—1999-2012

**eTable 7.** Age and Insurance-Adjusted Trends in Use of Any Prescription Drugs and Polypharmacy by Race/Ethnicity—1999-2012

**eTable 8.** Trends in the 25 Most Commonly Used Individual Prescription Medications in the Prior 30 Days—2011-2012

This supplementary material has been provided by the authors to give readers additional information about their work.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Narcotic analgesics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COX-2 inhibitors</td>
<td>2.0</td>
<td>4.4</td>
<td>4.4</td>
<td>1.3</td>
<td>1.0</td>
<td>0.4</td>
<td>&lt;.001</td>
<td>-0.6</td>
<td>0.28 (0.15, 0.5)</td>
<td></td>
</tr>
<tr>
<td><strong>Prescription analgesics</strong></td>
<td>12</td>
<td>13</td>
<td>17</td>
<td>12</td>
<td>12</td>
<td>11 (8.9, 13)</td>
<td>.018</td>
<td>-0.8</td>
<td>0.94 (0.76, 1.2)</td>
<td></td>
</tr>
<tr>
<td><strong>Antidepressants</strong></td>
<td>7.0</td>
<td>9.2</td>
<td>11</td>
<td>11</td>
<td>12</td>
<td>11</td>
<td>13 (11, 15)</td>
<td>&lt;.001</td>
<td>5.9 (3.4, 8.4)</td>
<td>1.8 (1.4, 2.3)</td>
</tr>
<tr>
<td><strong>Phenylpiperazine</strong></td>
<td>1.0</td>
<td>1.4</td>
<td>1.0</td>
<td>1.0</td>
<td>0.9</td>
<td>1.2 (0.9, 1.6)</td>
<td>.66</td>
<td>0.2</td>
<td>1.2 (0.89, 1.7)</td>
<td></td>
</tr>
<tr>
<td><strong>SSNRTs</strong></td>
<td>0.4</td>
<td>0.7</td>
<td>1.1</td>
<td>1.9</td>
<td>2.2</td>
<td>1.9</td>
<td>2.0 (1.6, 2.6)</td>
<td>&lt;.001</td>
<td>1.6 (1.0, 2.2)</td>
<td>4.5 (2.5, 8.0)</td>
</tr>
<tr>
<td><strong>SSRIs</strong></td>
<td>4.4</td>
<td>5.9</td>
<td>7.4</td>
<td>6.9</td>
<td>7.2</td>
<td>6.8</td>
<td>8.5 (6.9, 11)</td>
<td>&lt;.001</td>
<td>4.2 (2.2, 6.1)</td>
<td>1.9 (1.4, 2.5)</td>
</tr>
<tr>
<td><strong>Tricyclics</strong></td>
<td>1.3</td>
<td>1.5</td>
<td>1.5</td>
<td>1.1</td>
<td>1.3</td>
<td>1.0</td>
<td>1.3 (0.9, 1.8)</td>
<td>.33</td>
<td>0.0 (-0.6, 0.6)</td>
<td>1.0 (0.64, 1.6)</td>
</tr>
<tr>
<td><strong>Antihyperlipidemic agents</strong></td>
<td>8.2</td>
<td>10</td>
<td>12</td>
<td>14</td>
<td>17</td>
<td>17</td>
<td>17 (15, 18)</td>
<td>&lt;.001</td>
<td>8.6 (7.0, 10)</td>
<td>2.1 (1.8, 2.3)</td>
</tr>
<tr>
<td><strong>Fibrin acid derivatives</strong></td>
<td>0.8</td>
<td>1.1</td>
<td>1.1</td>
<td>1.0</td>
<td>1.5</td>
<td>1.5</td>
<td>1.6 (1.1, 2.3)</td>
<td>.011</td>
<td>0.8 (0.0, 1.5)</td>
<td>2.0 (1.0, 3.9)</td>
</tr>
<tr>
<td><strong>Statins</strong></td>
<td>7.4</td>
<td>9.2</td>
<td>11</td>
<td>13</td>
<td>15</td>
<td>15</td>
<td>16 (14, 17)</td>
<td>&lt;.001</td>
<td>8.2 (6.7, 9.6)</td>
<td>2.1 (1.9, 2.3)</td>
</tr>
<tr>
<td><strong>Antihyperlipidemic combinations</strong></td>
<td>-</td>
<td>-</td>
<td>0.04</td>
<td>1.0</td>
<td>1.8</td>
<td>0.9</td>
<td>0.5 (0.3, 1.0)</td>
<td>&lt;.001</td>
<td>0.5 (0.2, 0.8)</td>
<td></td>
</tr>
<tr>
<td><strong>P-trend</strong></td>
<td>9%</td>
<td>11%</td>
<td>12%</td>
<td>11%</td>
<td>12%</td>
<td>11%</td>
<td>13% (11, 15)</td>
<td>&lt;.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>COX inhibitors</strong></td>
<td>5.9</td>
<td>5.6</td>
<td>5.9</td>
<td>5.7</td>
<td>5.1</td>
<td>5.6</td>
<td>5.6 (4.2, 7.5)</td>
<td>.08</td>
<td>1.7 (-0.2, 3.5)</td>
<td>1.4 (1.0, 2.1)</td>
</tr>
</tbody>
</table>

© 2015 American Medical Association. All rights reserved.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prescription NSAIDs</strong></td>
<td>5.7%</td>
<td>3.8%</td>
<td>6.6%</td>
<td>4.5%</td>
<td>4.2%</td>
<td>4.4%</td>
<td>4.0% (3.2, 4.9)</td>
<td>.006</td>
<td>-1.8 (-3.0, -0.6)</td>
<td>0.71 (0.55, 0.93)</td>
</tr>
<tr>
<td>Salicylates</td>
<td>0.7%</td>
<td>0.7%</td>
<td>0.5%</td>
<td>0.6%</td>
<td>1.0%</td>
<td>1.5%</td>
<td>0.6 (0.4, 0.8)</td>
<td>.018</td>
<td>-0.1 (-0.4, 0.3)</td>
<td>0.87 (0.5, 1.5)</td>
</tr>
<tr>
<td>Miscellaneous analgesics</td>
<td>0.4%</td>
<td>0.4%</td>
<td>1.0%</td>
<td>0.8%</td>
<td>1.0%</td>
<td>1.2%</td>
<td>1.3 (1.0, 1.7)</td>
<td>&lt;.001</td>
<td>-9.9 (-12.5, -7.2)</td>
<td>0.27 (0.2, 0.36)</td>
</tr>
<tr>
<td><strong>Sex Hormones</strong></td>
<td>5.7%</td>
<td>3.8%</td>
<td>6.6%</td>
<td>4.5%</td>
<td>4.2%</td>
<td>4.4%</td>
<td>4.0% (3.2, 4.9)</td>
<td>.006</td>
<td>-1.8 (-3.0, -0.6)</td>
<td>0.71 (0.55, 0.93)</td>
</tr>
<tr>
<td><strong>Contraceptive hormones</strong></td>
<td>19%</td>
<td>21%</td>
<td>14%</td>
<td>12%</td>
<td>12%</td>
<td>10%</td>
<td>11 (8.9, 13)</td>
<td>&lt;.001</td>
<td>-8.4 (-11.6, -5.3)</td>
<td>0.56 (0.44, 0.71)</td>
</tr>
<tr>
<td><strong>Non-contraceptive hormones</strong></td>
<td>5%</td>
<td>9%</td>
<td>5%</td>
<td>7%</td>
<td>9%</td>
<td>5%</td>
<td>7% (4.7, 10)</td>
<td>&lt;.001</td>
<td>-9.9 (-12.5, -7.2)</td>
<td>0.27 (0.2, 0.36)</td>
</tr>
<tr>
<td>Antidiabetic agents</td>
<td>4.8%</td>
<td>5.6%</td>
<td>6.4%</td>
<td>6.3%</td>
<td>7.5%</td>
<td>7.3%</td>
<td>7.7 (6.9, 8.7)</td>
<td>&lt;.001</td>
<td>2.9 (1.6, 4.1)</td>
<td>1.6 (1.3, 1.9)</td>
</tr>
<tr>
<td>Biguanides</td>
<td>2.1%</td>
<td>2.6%</td>
<td>3.6%</td>
<td>3.6%</td>
<td>4.5%</td>
<td>4.5%</td>
<td>5.1 (4.5, 5.8)</td>
<td>&lt;.001</td>
<td>3.0 (2.2, 3.9)</td>
<td>2.4 (1.8, 3.2)</td>
</tr>
<tr>
<td>Insulin</td>
<td>1.2%</td>
<td>1.4%</td>
<td>1.5%</td>
<td>1.6%</td>
<td>2.0%</td>
<td>2.1%</td>
<td>2.5 (2.1, 2.9)</td>
<td>&lt;.001</td>
<td>1.3 (0.8, 1.8)</td>
<td>2.0 (1.4, 2.9)</td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td>2.8%</td>
<td>2.9%</td>
<td>3.3%</td>
<td>2.8%</td>
<td>3.2%</td>
<td>2.8%</td>
<td>3.0 (2.3, 3.8)</td>
<td>.96</td>
<td>0.1 (-0.7, 1.0)</td>
<td>1.0 (0.75, 1.5)</td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td>0.6%</td>
<td>1.0%</td>
<td>2.0%</td>
<td>1.9%</td>
<td>1.8%</td>
<td>1.1%</td>
<td>0.7 (0.5, 1.0)</td>
<td>.90</td>
<td>0.2 (-0.2, 0.5)</td>
<td>1.3 (0.73, 2.4)</td>
</tr>
<tr>
<td><strong>Prescription proton-pump inhibitors</strong></td>
<td>5.5%</td>
<td>5.5%</td>
<td>7.0%</td>
<td>7.1%</td>
<td>6.7%</td>
<td>6.9%</td>
<td>6.1 (5.1, 7.2)</td>
<td>.11</td>
<td>0.6 (-0.7, 1.9)</td>
<td>1.1 (0.89, 1.4)</td>
</tr>
<tr>
<td>Thyroid hormones</td>
<td>5.5%</td>
<td>5.5%</td>
<td>7.0%</td>
<td>7.1%</td>
<td>6.7%</td>
<td>6.9%</td>
<td>6.1 (5.1, 7.2)</td>
<td>.11</td>
<td>0.6 (-0.7, 1.9)</td>
<td>1.1 (0.89, 1.4)</td>
</tr>
<tr>
<td>Anxiolytics, Sedatives, Hypnotics</td>
<td>4.5%</td>
<td>4.5%</td>
<td>6.1%</td>
<td>5.5%</td>
<td>6.4%</td>
<td>6.0%</td>
<td>6.0 (5.0, 7.2)</td>
<td>.005</td>
<td>1.5 (0.1, 3.0)</td>
<td>1.3 (1.0, 1.8)</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>3.0%</td>
<td>3.2%</td>
<td>4.2%</td>
<td>3.4%</td>
<td>3.8%</td>
<td>3.8%</td>
<td>3.9 (3.3, 4.7)</td>
<td>.13</td>
<td>0.9 (0.0, 1.9)</td>
<td>1.3 (0.97, 1.8)</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>2.5%</td>
<td>3.6%</td>
<td>4.6%</td>
<td>4.2%</td>
<td>5.3%</td>
<td>5.2%</td>
<td>5.4 (4.6, 6.4)</td>
<td>&lt;.001</td>
<td>2.9 (1.9, 3.9)</td>
<td>2.2 (1.7, 2.9)</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>1.3%</td>
<td>1.6%</td>
<td>2.1%</td>
<td>1.8%</td>
<td>1.9%</td>
<td>2.1%</td>
<td>2.2 (1.8, 2.8)</td>
<td>.006</td>
<td>0.9 (0.3, 1.6)</td>
<td>1.7 (1.2, 2.6)</td>
</tr>
<tr>
<td>Gamma-aminobutyric acid analogs</td>
<td>0.3%</td>
<td>1.0%</td>
<td>1.2%</td>
<td>1.2%</td>
<td>1.8%</td>
<td>1.8%</td>
<td>2.0 (1.5, 2.5)</td>
<td>&lt;.001</td>
<td>1.7 (1.1, 2.2)</td>
<td>6.5 (2.4, 17)</td>
</tr>
<tr>
<td><strong>Bronchodilators</strong></td>
<td>3.3%</td>
<td>3.4%</td>
<td>3.9%</td>
<td>4.4%</td>
<td>4.9%</td>
<td>4.5%</td>
<td>4.9 (4.0, 6.1)</td>
<td>&lt;.001</td>
<td>1.7 (0.4, 2.9)</td>
<td>1.5 (1.1, 2.1)</td>
</tr>
<tr>
<td>Adrenergic bronchodilators</td>
<td>2.9%</td>
<td>3.2%</td>
<td>3.7%</td>
<td>4.2%</td>
<td>4.7%</td>
<td>4.3%</td>
<td>4.7 (3.7, 5.9)</td>
<td>&lt;.001</td>
<td>1.8 (0.5, 3.0)</td>
<td>1.6 (1.1, 2.2)</td>
</tr>
<tr>
<td>Anticholinergic bronchodilators</td>
<td>0.6%</td>
<td>0.6%</td>
<td>1.1%</td>
<td>1.0%</td>
<td>1.3%</td>
<td>0.9%</td>
<td>1.1 (0.7, 1.6)</td>
<td>.006</td>
<td>0.4 (0.0, 0.9)</td>
<td>1.7 (1.1, 2.6)</td>
</tr>
<tr>
<td>Bronchodilator combinations</td>
<td>0.3%</td>
<td>0.6%</td>
<td>1.9%</td>
<td>1.9%</td>
<td>2.1%</td>
<td>2.0%</td>
<td>2.0 (1.4, 2.7)</td>
<td>&lt;.001</td>
<td>1.7 (1.1, 2.3)</td>
<td>7.2 (4.2, 12)</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>---------------------------</td>
<td>---------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Antibiotics</td>
<td>5.6</td>
<td>5.6</td>
<td>5.6</td>
<td>5.4</td>
<td>4.3</td>
<td>4.0</td>
<td>4.3</td>
<td>3.7, 4.9</td>
<td>&lt;.001</td>
<td>0.76 (0.64, 0.91)</td>
</tr>
<tr>
<td>Oral antibiotics</td>
<td>3.7</td>
<td>3.6</td>
<td>3.7</td>
<td>3.4</td>
<td>2.8</td>
<td>2.7</td>
<td>3.0</td>
<td>2.6, 3.4</td>
<td>.001</td>
<td>0.80 (0.65, 0.99)</td>
</tr>
<tr>
<td>Antiarrhythmic agents</td>
<td>5.4</td>
<td>4.9</td>
<td>4.4</td>
<td>4.5</td>
<td>3.4</td>
<td>3.0</td>
<td>2.7</td>
<td>2.1, 3.4</td>
<td>&lt;.001</td>
<td>0.49 (0.38, 0.62)</td>
</tr>
<tr>
<td>Class IV</td>
<td>2.9</td>
<td>2.6</td>
<td>2.1</td>
<td>2.2</td>
<td>1.2</td>
<td>1.4</td>
<td>1.0</td>
<td>0.7, 1.4</td>
<td>&lt;.001</td>
<td>0.33 (0.21, 0.47)</td>
</tr>
<tr>
<td>Class V</td>
<td>1.6</td>
<td>1.2</td>
<td>1.2</td>
<td>0.9</td>
<td>0.7</td>
<td>0.5</td>
<td>0.7</td>
<td>0.4, 1.0</td>
<td>&lt;.001</td>
<td>0.41 (0.24, 0.63)</td>
</tr>
<tr>
<td>Coagulation modifiers</td>
<td>2.5</td>
<td>2.9</td>
<td>3.4</td>
<td>3.9</td>
<td>4.8</td>
<td>4.7</td>
<td>3.9</td>
<td>3.4, 4.4</td>
<td>&lt;.001</td>
<td>1.4 (0.7, 2.1)</td>
</tr>
<tr>
<td>Anticoagulants</td>
<td>1.4</td>
<td>1.7</td>
<td>1.5</td>
<td>1.8</td>
<td>1.9</td>
<td>1.9</td>
<td>1.7</td>
<td>1.4, 2.1</td>
<td>.19</td>
<td>1.2 (0.77, 1.7)</td>
</tr>
<tr>
<td>Warfarin</td>
<td>1.4</td>
<td>1.6</td>
<td>1.5</td>
<td>1.8</td>
<td>1.9</td>
<td>1.8</td>
<td>1.6</td>
<td>1.2, 2.0</td>
<td>.36</td>
<td>1.1 (0.68, 1.7)</td>
</tr>
<tr>
<td>Antiplatelet agents</td>
<td>1.0</td>
<td>1.2</td>
<td>1.8</td>
<td>2.2</td>
<td>2.8</td>
<td>3.0</td>
<td>2.2</td>
<td>1.8, 2.7</td>
<td>&lt;.001</td>
<td>1.2 (0.7, 1.7)</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>0.3</td>
<td>0.6</td>
<td>1.3</td>
<td>1.6</td>
<td>1.9</td>
<td>1.3</td>
<td>1.4</td>
<td>1.2, 1.8</td>
<td>&lt;.001</td>
<td>1.1 (0.8, 1.5)</td>
</tr>
<tr>
<td>Muscle relaxants</td>
<td>1.3</td>
<td>1.6</td>
<td>2.5</td>
<td>2.2</td>
<td>2.1</td>
<td>2.0</td>
<td>2.5</td>
<td>1.8, 3.4</td>
<td>.011</td>
<td>1.2 (0.3, 2.1)</td>
</tr>
<tr>
<td>Nasal preparations</td>
<td>1.9</td>
<td>2.0</td>
<td>2.5</td>
<td>3.4</td>
<td>2.3</td>
<td>2.2</td>
<td>2.4</td>
<td>1.8, 3.2</td>
<td>.31</td>
<td>1.3 (0.91, 1.9)</td>
</tr>
<tr>
<td>Nasal steroids</td>
<td>1.8</td>
<td>2.0</td>
<td>2.4</td>
<td>3.2</td>
<td>2.1</td>
<td>2.0</td>
<td>2.2</td>
<td>1.7, 2.8</td>
<td>.62</td>
<td>1.2 (0.87, 1.7)</td>
</tr>
<tr>
<td>H2 antagonists</td>
<td>2.2</td>
<td>1.9</td>
<td>2.4</td>
<td>1.6</td>
<td>2.1</td>
<td>3.0</td>
<td>2.4</td>
<td>1.9, 3.1</td>
<td>.20</td>
<td>1.1 (0.71, 1.5)</td>
</tr>
<tr>
<td>Prescription antihistamines</td>
<td>3.9</td>
<td>5.0</td>
<td>4.2</td>
<td>4.4</td>
<td>3.9</td>
<td>2.8</td>
<td>2.1</td>
<td>1.6, 2.7</td>
<td>&lt;.001</td>
<td>0.53 (0.40, 0.70)</td>
</tr>
<tr>
<td>Peripherally-acting antiadrenergic agents</td>
<td>1.7</td>
<td>1.6</td>
<td>1.7</td>
<td>1.7</td>
<td>2.0</td>
<td>1.9</td>
<td>2.0</td>
<td>1.6, 2.6</td>
<td>.19</td>
<td>1.1 (0.80, 1.6)</td>
</tr>
<tr>
<td>5-alpha reductase inhibitors</td>
<td>0.4</td>
<td>0.6</td>
<td>0.8</td>
<td>1.0</td>
<td>1.7</td>
<td>1.5</td>
<td>2.2</td>
<td>1.7, 2.9</td>
<td>&lt;.001</td>
<td>1.8 (1.1, 2.4)</td>
</tr>
<tr>
<td>Antiemetic/Antivertigo agents</td>
<td>2.0</td>
<td>2.1</td>
<td>2.0</td>
<td>1.9</td>
<td>2.3</td>
<td>1.8</td>
<td>2.0</td>
<td>1.5, 2.6</td>
<td>.92</td>
<td>1.0 (0.68, 1.6)</td>
</tr>
<tr>
<td>CNS stimulants</td>
<td>0.4</td>
<td>0.6</td>
<td>0.5</td>
<td>0.9</td>
<td>1.1</td>
<td>0.8</td>
<td>1.8</td>
<td>1.2, 2.7</td>
<td>&lt;.001</td>
<td>1.4 (0.5, 2.2)</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>1.3</td>
<td>1.2</td>
<td>1.2</td>
<td>1.4</td>
<td>1.4</td>
<td>1.3</td>
<td>1.7</td>
<td>1.3, 2.2</td>
<td>.20</td>
<td>1.3 (0.74, 2.4)</td>
</tr>
<tr>
<td>Atypical Antipsychotics</td>
<td>0.6</td>
<td>0.8</td>
<td>0.8</td>
<td>1.1</td>
<td>1.2</td>
<td>1.0</td>
<td>1.3</td>
<td>1.1, 1.7</td>
<td>.007</td>
<td>2.2 (1.1, 4.4)</td>
</tr>
</tbody>
</table>

© 2015 American Medical Association. All rights reserved.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td></td>
<td>% (95% CI)</td>
<td>% (95% CI)</td>
</tr>
<tr>
<td><strong>Glucocorticoids</strong></td>
<td>2.3</td>
<td>1.9</td>
<td>1.6</td>
<td>1.6</td>
<td>1.2</td>
<td>1.2</td>
<td>1.5</td>
<td>1.5</td>
<td>(1.1, 1.9)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>Prescription ophthalmic preparations</strong></td>
<td>1.1</td>
<td>1.2</td>
<td>1.5</td>
<td>1.4</td>
<td>1.4</td>
<td>1.5</td>
<td>1.4</td>
<td>1.4</td>
<td>(1.1, 1.7)</td>
<td>.13</td>
</tr>
<tr>
<td><strong>Ophthalmic glaucoma agents</strong></td>
<td>0.9</td>
<td>1.0</td>
<td>1.2</td>
<td>1.1</td>
<td>1.0</td>
<td>1.0</td>
<td>0.9</td>
<td>0.9</td>
<td>(0.7, 1.2)</td>
<td>.87</td>
</tr>
<tr>
<td><strong>Antiviral agents</strong></td>
<td>0.5</td>
<td>0.5</td>
<td>0.3</td>
<td>0.6</td>
<td>0.7</td>
<td>0.7</td>
<td>1.3</td>
<td>1.3</td>
<td>(0.9, 1.8)</td>
<td>.001</td>
</tr>
<tr>
<td><strong>Antiparkinson agents</strong></td>
<td>0.7</td>
<td>0.6</td>
<td>0.5</td>
<td>0.8</td>
<td>1.0</td>
<td>0.8</td>
<td>1.3</td>
<td>1.3</td>
<td>(0.9, 1.9)</td>
<td>.004</td>
</tr>
<tr>
<td><strong>Prescription dermatologic agents</strong></td>
<td>1.0</td>
<td>1.4</td>
<td>1.8</td>
<td>1.2</td>
<td>0.9</td>
<td>1.3</td>
<td>1.2</td>
<td>1.2</td>
<td>(0.8, 1.8)</td>
<td>.67</td>
</tr>
<tr>
<td><strong>Antigout agents</strong></td>
<td>0.7</td>
<td>1.2</td>
<td>0.7</td>
<td>1.2</td>
<td>1.3</td>
<td>1.3</td>
<td>1.3</td>
<td>1.3</td>
<td>(0.7, 1.4)</td>
<td>.10</td>
</tr>
<tr>
<td><strong>Leukotriene modifiers</strong></td>
<td>0.4</td>
<td>0.8</td>
<td>1.1</td>
<td>1.2</td>
<td>1.1</td>
<td>1.2</td>
<td>1.0</td>
<td>1.0</td>
<td>(0.7, 1.5)</td>
<td>.007</td>
</tr>
<tr>
<td><strong>Urinary antispasmodics</strong></td>
<td>0.9</td>
<td>0.7</td>
<td>0.8</td>
<td>1.1</td>
<td>1.1</td>
<td>1.0</td>
<td>0.8</td>
<td>0.8</td>
<td>(0.5, 1.3)</td>
<td>.35</td>
</tr>
<tr>
<td><strong>Antianginal agents</strong></td>
<td>1.7</td>
<td>1.4</td>
<td>1.2</td>
<td>1.1</td>
<td>0.8</td>
<td>0.6</td>
<td>0.7</td>
<td>0.7</td>
<td>(0.5, 1.0)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>Bone-resorption inhibitors</strong></td>
<td>0.6</td>
<td>1.5</td>
<td>2.2</td>
<td>2.1</td>
<td>2.2</td>
<td>1.6</td>
<td>0.8</td>
<td>0.8</td>
<td>(0.5, 1.1)</td>
<td>.92</td>
</tr>
<tr>
<td><strong>Antineoplastic hormones</strong></td>
<td>2.2</td>
<td>2.0</td>
<td>1.4</td>
<td>1.1</td>
<td>1.1</td>
<td>1.1</td>
<td>0.7</td>
<td>0.7</td>
<td>(0.4, 1.0)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>Inotropic agents (Digoxin)</strong></td>
<td>1.6</td>
<td>1.2</td>
<td>1.2</td>
<td>0.9</td>
<td>0.7</td>
<td>0.5</td>
<td>0.7</td>
<td>0.7</td>
<td>(0.4, 1.0)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td><strong>Respiratory-inhalant products</strong></td>
<td>0.9</td>
<td>1.2</td>
<td>0.8</td>
<td>0.8</td>
<td>0.9</td>
<td>0.7</td>
<td>0.7</td>
<td>0.7</td>
<td>(0.4, 1.1)</td>
<td>.023</td>
</tr>
<tr>
<td><strong>Inhaled corticosteroids</strong></td>
<td>0.9</td>
<td>1.1</td>
<td>0.7</td>
<td>0.7</td>
<td>0.8</td>
<td>0.6</td>
<td>0.6</td>
<td>0.6</td>
<td>(0.4, 1.1)</td>
<td>.030</td>
</tr>
<tr>
<td><strong>Selective estrogen receptor modulators</strong></td>
<td>1.2</td>
<td>1.7</td>
<td>1.4</td>
<td>1.3</td>
<td>1.2</td>
<td>1.0</td>
<td>0.5</td>
<td>0.5</td>
<td>(0.3, 1.0)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

**ABBREVIATION:** ACE (Angiotensin Converting Enzyme); COX-2 (Cyclooxygenase-2); NSAID (Non-Steroidal Anti-Inflammatory Drug); SSNRI (Selective Serotonin–Norepinephrine Reuptake Inhibitor); SSRI (Selective Serotonin Reuptake Inhibitor)

<sup>a</sup> Age-adjusted using standardization and the 2000 US Standard Population (based on 5-year age groups, up to 80y+).
b All data are weighted to be nationally representative.
c Overarching drug classes are presented in order of descending prevalence in 2011-2012.
d Difference in prevalence represents the absolute increase or decrease in prevalence of use between 1999-2000 and 2011-2012.
e Prevalence ratio represents the relative increase or decrease in prevalence of use between 1999-2000 and 2011-2012.
f Excludes COX-2 inhibitors.
g Analyses limited to women.
h Analyses limited to men.
<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Trend 1&lt;sup&gt;b,c&lt;/sup&gt;</th>
<th>Trend 2&lt;sup&gt;b,c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antihypertensive agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-hypertensive agents</td>
<td>3.2 (1.8, 4.6)</td>
<td>-</td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>5.4 (4.0, 6.7)</td>
<td>2003-2004 11 (3.1, 19)</td>
</tr>
<tr>
<td>Angiotensin II inhibitors</td>
<td>7.9 (-0.9, 17)</td>
<td>2007-2008 14 (-4.6, 35)</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>5.6 (1.8, 9.6)</td>
<td>2003-2004 13 (-8.3, 39)</td>
</tr>
<tr>
<td>Cardioselective</td>
<td>4.6 (2.2, 7.0)</td>
<td>2005-2006 11 (3.7, 19)</td>
</tr>
<tr>
<td>Non-cardioselective</td>
<td>6.8 (1.9, 12)</td>
<td>-</td>
</tr>
<tr>
<td>Calcium-channel blockers</td>
<td>0.5 (-1.0, 2.0)</td>
<td>-</td>
</tr>
<tr>
<td>Any diuretic</td>
<td>3.2 (1.7, 4.7)</td>
<td>2003-2004 7.5 (-1.3, 17.1)</td>
</tr>
<tr>
<td>Loop</td>
<td>0.8 (-1.1, 2.8)</td>
<td>-</td>
</tr>
<tr>
<td>Loop</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Potassium-sparing</td>
<td>-2.3 (-5.3, 0.7)</td>
<td>-</td>
</tr>
<tr>
<td>Thiazide</td>
<td>4.6 (3.0, 6.2)</td>
<td>2003-2004 9.9 (0.2, 20.6)</td>
</tr>
<tr>
<td>Antihypertensive combinations</td>
<td>3.7 (-0.1, 7.6)</td>
<td>-</td>
</tr>
<tr>
<td>Antihyperlipidemic agents</td>
<td>7.4 (6.2, 8.6)</td>
<td>2007-2008 10 (8.1, 13)</td>
</tr>
<tr>
<td>Statins</td>
<td>8.1 (7.6, 8.5)</td>
<td>2005-2006 12 (11, 14)</td>
</tr>
<tr>
<td>Fibric acid derivatives</td>
<td>6.4 (2.9, 10)</td>
<td>-</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>4.6 (0.2, 9.1)</td>
<td>2003-2004 13 (-11, 43)</td>
</tr>
<tr>
<td>SSNRIs</td>
<td>15 (9.5, 20)</td>
<td>2005-2006 32 (10, 57)</td>
</tr>
<tr>
<td>SSRIs</td>
<td>4.1 (0.4, 8.0)</td>
<td>-</td>
</tr>
<tr>
<td>Tricyclics</td>
<td>-0.6 (-4.7, 3.7)</td>
<td>-</td>
</tr>
<tr>
<td>Analgesics</td>
<td>-0.2 (-3.6, 3.4)</td>
<td>-</td>
</tr>
<tr>
<td>COX-2 inhibitors</td>
<td>-17 (-32, 0.8)</td>
<td>-</td>
</tr>
<tr>
<td>Narcotic analgesics</td>
<td>2.9 (-0.6, 6.7)</td>
<td>2003-2004 12 (-8.2, 36)</td>
</tr>
<tr>
<td>Prescription NSAIDs</td>
<td>-1.7 (-6.6, 3.4)</td>
<td>-</td>
</tr>
<tr>
<td>Salicylates</td>
<td>6.4 (-3.5, 17)</td>
<td>-</td>
</tr>
<tr>
<td>Miscellaneous analgesics</td>
<td>11.3 (4.8, 18)</td>
<td>-</td>
</tr>
<tr>
<td>Sex hormones&lt;sup&gt;e&lt;/sup&gt;</td>
<td>-5.9 (-8.7, -2.9)</td>
<td>-</td>
</tr>
<tr>
<td>Contraceptive hormones&lt;sup&gt;e&lt;/sup&gt;</td>
<td>-1.2 (-3.0, 0.6)</td>
<td>-</td>
</tr>
<tr>
<td>Non-contraceptive hormones&lt;sup&gt;e&lt;/sup&gt;</td>
<td>-12 (-18, -7.1)</td>
<td>-</td>
</tr>
<tr>
<td>Antidiabetic Agents</td>
<td>4.7 (3.1, 6.2)</td>
<td>-</td>
</tr>
<tr>
<td>Biguanides</td>
<td>7.9 (5.2, 11)</td>
<td>-</td>
</tr>
<tr>
<td>Insulin</td>
<td>7.1 (5.9, 8.4)</td>
<td>-</td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td>1.7 (-0.1, 3.4)</td>
<td>-</td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td>7.1 (-2.4, 18)</td>
<td>2003-2004 48 (-15, 156)</td>
</tr>
<tr>
<td>Prescription proton pump inhibitors</td>
<td>4.8 (0.7, 9.2)</td>
<td>-</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>7.3 (2.0, 13)</td>
<td>2003-2004 16 (-14, 58)</td>
</tr>
<tr>
<td>Benzodiazapines</td>
<td>4.3 (1.8, 6.8)</td>
<td>-</td>
</tr>
<tr>
<td>Gamma-aminobutyric acid analogs</td>
<td>9.7 (4.8, 15)</td>
<td>-</td>
</tr>
<tr>
<td>Bronchodilators</td>
<td>4.4 (2.3, 6.6)</td>
<td>-</td>
</tr>
<tr>
<td>Adrenergic bronchodilators</td>
<td>4.0 (3.1, 4.8)</td>
<td>2007-2008 6.6 (5.3, 8.0)</td>
</tr>
<tr>
<td>Anti-cholinergic bronchodilators</td>
<td>7.4 (1.4, 14)</td>
<td>-</td>
</tr>
<tr>
<td>Bronchodilator combinations</td>
<td>20 (14, 26)</td>
<td>2003-2004 66 (24, 122)</td>
</tr>
</tbody>
</table>

<sup>a</sup> eTable 2. Results of Joinpoint Trend Analysis for Selected Prescription Drugs

<sup>b</sup> Average Annual Percent Change (AAPC) (95% CI)

<sup>c</sup> End of trend

<sup>d</sup> Annual Percent Change (APC) (95% CI)
<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Trend 1&lt;sup&gt;b,c&lt;/sup&gt;</th>
<th>Trend 2&lt;sup&gt;b,c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Average Annual Percent Change (AAPC) (95% CI)&lt;sup&gt;d&lt;/sup&gt;</td>
<td>End of trend&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Muscle relaxants</td>
<td>4.8 (-0.9, 11)</td>
<td>2003-2004</td>
</tr>
</tbody>
</table>

<sup>a</sup> Overarching drug classes are presented in order of descending prevalence in 2011-2012.

<sup>b</sup> Disaggregated trend presented if p-value from permutation test indicates that the model with a joinpoint is more informative than the model without a joinpoint (i.e., p-value < 0.05).

<sup>c</sup> In the presence of a significant joinpoint, the starting point for Trend 1 is always 1999-2000. For Trend 2, the ending point is always 2011-2012 and the starting point is the same as the ending point for Trend 1 (i.e., the joinpoint). There were no drug classes with more than 1 joinpoint indicated.

<sup>d</sup> In the absence of a joinpoint, the AAPC is equivalent to the APC over the entire period.

<sup>e</sup> Analysis limited to women.
<p>| Sex hormones | 0.7 (0.5, 1.0) | &lt;0.001 | 2.2 (1.1, 4.2) | 5.3 (3.1, 9.0) | &lt;0.001 | 1.7 (1.0, 2.9) | 1.5 (1.4, 3.5) | &lt;0.001 | 2.0 (0.7, 5.9) | &lt;0.001 | 1.9 (1.6, 2.2) |
| Narcotic analgesics | 0.9 (0.7, 1.2) | &lt;0.001 | 1.2 (0.9, 1.5) | 1.4 (1.1, 1.6) | &lt;0.001 | 2.0 (1.4, 2.7) | 0.8 (0.7, 1.0) | &lt;0.001 | 2.4 (1.4, 4.0) | &lt;0.001 | 1.7 (1.4, 2.0) |
| Antihyperlipidemic agents | 0.8 (0.7, 0.9) | 0.11 | 1.6 (1.4, 1.8) | 1.3 (1.1, 1.5) | 0.001 | 2.0 (1.1, 2.7) | 1.4 (1.1, 1.7) | &lt;0.001 | 4.0 (2.6, 6.3) | &lt;0.001 | 1.8 (1.5, 2.2) |
| Antidiabetic agents | 0.3 (0.2, 0.4) | 0.02 | 1.2 (0.9, 1.5) | 1.3 (1.1, 1.5) | &lt;0.001 | 2.0 (1.1, 2.7) | 1.4 (1.1, 1.7) | &lt;0.001 | 4.0 (2.6, 6.3) | &lt;0.001 | 1.8 (1.5, 2.2) |
| Biguanides | 0.8 (0.5, 1.3) | 0.24 | 1.6 (1.3, 1.9) | 1.3 (1.1, 1.5) | &lt;0.001 | 2.0 (1.1, 2.7) | 1.4 (1.1, 1.7) | &lt;0.001 | 4.0 (2.6, 6.3) | &lt;0.001 | 1.8 (1.5, 2.2) |
| Sulfonylureas | 0.1 (0.0, 0.3) | 0.02 | 1.2 (0.9, 1.5) | 1.3 (1.1, 1.5) | &lt;0.001 | 2.0 (1.1, 2.7) | 1.4 (1.1, 1.7) | &lt;0.001 | 4.0 (2.6, 6.3) | &lt;0.001 | 1.8 (1.5, 2.2) |</p>
<table>
<thead>
<tr>
<th></th>
<th>Age 20-39</th>
<th>Age 40-64</th>
<th>Age 65+</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1999-2000</td>
<td>2011-2012</td>
<td>P-trend</td>
</tr>
<tr>
<td>Prescription proton-pump inhibitors</td>
<td>.14</td>
<td>.04</td>
<td>2.2 (1.3, 3.6)</td>
</tr>
<tr>
<td>Thyroid hormones</td>
<td>.01</td>
<td>.00</td>
<td>1.0 (-.8, 2.1)</td>
</tr>
<tr>
<td>Antipsychotics/Antiemetic/Antivertigo</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Antibiotics</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Bronchodilators</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Benzodiazapines</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Bronchodilators</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Antibiotics</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Oral antibiotics</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Antihypertensive agents</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Coagulation modifiers</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Anticoagulants</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Warfarin</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Antithrombin agents</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Muscle relaxants</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Nasal preparations</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Nasal steroids</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>H2 antagonists</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Prescription antihistamines</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Antihistamines/Antivertigo agents</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>.17</td>
<td>.12</td>
<td>1.2 (1.0, 2.7)</td>
</tr>
</tbody>
</table>

© 2015 American Medical Association. All rights reserved.
<table>
<thead>
<tr>
<th>Age 20-39</th>
<th>Age 40-64</th>
<th>Age 65+</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>%</td>
<td>% (95% CI)</td>
</tr>
<tr>
<td>Prescription Ophthalmic preparations</td>
<td>0.1</td>
<td>0.3 (0.1, 0.8)</td>
</tr>
</tbody>
</table>

**ABBREVIATION:** ACE (Angiotensin Converting Enzyme); COX-2 (Cyclooxygenase-2); NSAID (Non-Steroidal Anti-Inflammatory Drug); SSNRI (Selective Serotonin-Norepinephrine Reuptake Inhibitor); SSRI (Selective Serotonin Reuptake Inhibitor)

*a* All data are weighted to be nationally representative.

*b* Overarching drug classes are presented in order of descending prevalence in 2011-2012.

*c* Difference in prevalence represents the absolute increase or decrease in prevalence of use between 1999-2000 and 2011-2012.

*d* Prevalence ratio represents the relative increase or decrease in prevalence of use between 1999-2000 and 2011-2012.

*e* Excludes COX-2 inhibitors

*f* Analyses limited to women

- No use

¶ Data withheld due to relative standard error >30%; Results for a given survey cycle are not presented if the relative standard error (RSE=[SE of prevalence/prevalence]×100) exceeds 30%, consistent with NHANES analytic guidelines.23
### eTable 4. Trends in Use of Prescription Drugs in the Prior 30 Days Among US Adults by Sex—1999-2012a,b

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1999-2000 (n=2,261) %</td>
<td>2011-2012 (n=2,739) %</td>
</tr>
<tr>
<td></td>
<td>(95% CI)</td>
<td>(95% CI)</td>
</tr>
<tr>
<td></td>
<td>P-trend</td>
<td>Difference in Prevalencec % (95% CI)</td>
</tr>
<tr>
<td>Any prescription</td>
<td>.03</td>
<td>5.7 (0.7, 11)</td>
</tr>
<tr>
<td>≥5 prescriptions</td>
<td>.03</td>
<td>5.7 (0.7, 11)</td>
</tr>
<tr>
<td>Antihypertensive agents</td>
<td>&lt;.001</td>
<td>8.0 (3.6, 12)</td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>&lt;.001</td>
<td>7.0 (4.7, 9.2)</td>
</tr>
<tr>
<td>Angiotensin II inhibitors</td>
<td>&lt;.001</td>
<td>2.9 (1.3, 4.5)</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>&lt;.001</td>
<td>4.2 (1.4, 7.0)</td>
</tr>
<tr>
<td>Cardioselective</td>
<td>.01</td>
<td>2.9 (0.5, 5.4)</td>
</tr>
<tr>
<td>Non-cardioselective</td>
<td>.1</td>
<td>2.0 (1.3, 3.0)</td>
</tr>
<tr>
<td>Calcium-channel blockers</td>
<td>.03</td>
<td>0.9 (-0.9, 2.7)</td>
</tr>
<tr>
<td>Any diuretic</td>
<td>&lt;.001</td>
<td>3.4 (1.5, 5.7)</td>
</tr>
<tr>
<td>Loop</td>
<td>.45</td>
<td>0.1 (-1.1, 0.9)</td>
</tr>
<tr>
<td>Potassium-sparing</td>
<td>.84</td>
<td>0.3 (-1.0, 0.3)</td>
</tr>
<tr>
<td>Thiazide</td>
<td>&lt;.001</td>
<td>3.5 (1.6, 5.4)</td>
</tr>
<tr>
<td>Antihypertensive combinations</td>
<td>.01</td>
<td>1.7 (0.2, 3.3)</td>
</tr>
<tr>
<td>Statins</td>
<td>.01</td>
<td>10 (7.3, 14)</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>&lt;.001</td>
<td>4.8 (2.6, 6.9)</td>
</tr>
<tr>
<td>SSNRIs</td>
<td>&lt;.001</td>
<td>4.6 (2.1, 3.8)</td>
</tr>
<tr>
<td>SSRIs</td>
<td>&lt;.001</td>
<td>2.7 (2.2, 3.2)</td>
</tr>
<tr>
<td>Prescription analgesics</td>
<td>&lt;.001</td>
<td>2.3 (1.9, 2.7)</td>
</tr>
<tr>
<td>Narcotic analgesics</td>
<td>&lt;.001</td>
<td>2.6 (1.2, 3.0)</td>
</tr>
<tr>
<td>Prescription NSAIDs*</td>
<td>.01</td>
<td>2.3 (1.9, 2.7)</td>
</tr>
<tr>
<td>Antidiabetic agents</td>
<td>&lt;.001</td>
<td>4.5 (2.6, 6.4)</td>
</tr>
<tr>
<td>Biguanides</td>
<td>&lt;.001</td>
<td>3.5 (2.1, 4.9)</td>
</tr>
<tr>
<td>Insulin</td>
<td>&lt;.001</td>
<td>1.7 (0.5, 2.9)</td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td>.1</td>
<td>1.1 (0.2, 2.1)</td>
</tr>
<tr>
<td>Prescription proton-pump inhibitors</td>
<td>&lt;.001</td>
<td>3.6 (1.1, 6.0)</td>
</tr>
<tr>
<td>Thyroid hormones</td>
<td>.04</td>
<td>1.2 (-0.2, 2.7)</td>
</tr>
</tbody>
</table>
### Table: Prevalence of Prescription Medications

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th></th>
<th>Female</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=2,281)</td>
<td>(n=2,739)</td>
<td>(n=2,600)</td>
<td>(n=2,819)</td>
</tr>
<tr>
<td></td>
<td>%</td>
<td>(95% CI)</td>
<td>%</td>
<td>(95% CI)</td>
</tr>
<tr>
<td><strong>Anxiolytics, Sedatives, Hypnotics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>3.0</td>
<td>5.3 (4.0, 7.0)</td>
<td>.002</td>
<td>2.3 (0.5, 4.1)</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>1.8</td>
<td>4.9 (3.9, 6.2)</td>
<td>&lt;.001</td>
<td>3.1 (1.9, 4.4)</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>0.8</td>
<td>2.0 (1.3, 3)</td>
<td>.02</td>
<td>1.1 (0.2, 2.1)</td>
</tr>
<tr>
<td>Bronchodilators</td>
<td>2.3</td>
<td>5.0 (3.6, 6.9)</td>
<td>&lt;.001</td>
<td>2.7 (0.9, 4.5)</td>
</tr>
<tr>
<td>Antibiotics</td>
<td>1.9</td>
<td>4.8 (3.4, 6.8)</td>
<td>&lt;.001</td>
<td>2.9 (1.1, 4.7)</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>0.2</td>
<td>2.2 (1.3, 3.7)</td>
<td>&lt;.001</td>
<td>2.0 (0.8, 3.1)</td>
</tr>
<tr>
<td><strong>Anticoagulants</strong></td>
<td>4.6</td>
<td>3.7 (2.7, 5.0)</td>
<td>.047</td>
<td>-0.9 (-2.3, 0.5)</td>
</tr>
<tr>
<td>Oral antibiotics</td>
<td>3.2</td>
<td>2.6 (1.8, 3.7)</td>
<td>&lt;.19</td>
<td>-0.6 (1.9, 0.7)</td>
</tr>
<tr>
<td><strong>Antihypertensives</strong></td>
<td>4.6</td>
<td>2.7 (1.8, 4)</td>
<td>&lt;.001</td>
<td>-1.9 (-3.4, -0.4)</td>
</tr>
<tr>
<td><strong>Coagulation modifiers</strong></td>
<td>2.3</td>
<td>4.1 (3.5, 5.7)</td>
<td>&lt;.001</td>
<td>1.8 (0.2, 3.3)</td>
</tr>
<tr>
<td>Warfarin</td>
<td>1.4</td>
<td>1.4 (0.9, 2.3)</td>
<td>&lt;.24</td>
<td>0.0 (-0.9, 1.0)</td>
</tr>
<tr>
<td>Antiplatelet agents</td>
<td>0.9</td>
<td>2.7 (1.9, 3.8)</td>
<td>&lt;.001</td>
<td>1.8 (0.8, 2.8)</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>1.3</td>
<td>1.9 (1.3, 2.9)</td>
<td>&lt;.001</td>
<td>1.7 (0.9, 2.5)</td>
</tr>
<tr>
<td><strong>Muscle relaxants</strong></td>
<td>1.3</td>
<td>1.7 (1.1, 2.8)</td>
<td>.27</td>
<td>0.5 (-0.6, 1.5)</td>
</tr>
<tr>
<td><strong>H2 Antagonists</strong></td>
<td>1.5</td>
<td>1.7 (0.9, 3.2)</td>
<td>.93</td>
<td>0.3 (-0.9, 1.5)</td>
</tr>
<tr>
<td><strong>Glucocorticoids</strong></td>
<td>1.5</td>
<td>1.5 (0.8, 2.8)</td>
<td>.70</td>
<td>0.0 (-1.0, 1.1)</td>
</tr>
<tr>
<td><strong>Prescription antihistamines</strong></td>
<td>1.7</td>
<td>2.1 (1.6, 2.8)</td>
<td>.04</td>
<td>0.4 (-0.4, 1.1)</td>
</tr>
<tr>
<td><strong>Antiemetic/Antivertigo agents</strong></td>
<td>2.8</td>
<td>1.4 (0.8, 2.2)</td>
<td>&lt;.001</td>
<td>-1.4 (-2.5, -0.3)</td>
</tr>
<tr>
<td><strong>Antipsychotics</strong></td>
<td>1.2</td>
<td>1.4 (0.9, 2.1)</td>
<td>.62</td>
<td>0.2 (-0.5, 0.9)</td>
</tr>
<tr>
<td><strong>Glaucomatous preparations</strong></td>
<td>2.0</td>
<td>1.5 (1.0, 2.4)</td>
<td>.04</td>
<td>-0.5 (-1.4, 0.4)</td>
</tr>
</tbody>
</table>

**Note:** All data are weighted to be nationally representative.

**Abbreviations:** ACE (Angiotensin Converting Enzyme); COX-2 (Cyclooxygenase-2); NSAID (Non-Steroidal Anti-Inflammatory Drug); SSNRI (Selective Serotonin–Norepinephrine Reuptake Inhibitor); SSRI (Selective Serotonin Reuptake Inhibitor)

**P-values:** <.001 < .01 < .05 < .1 < .2
Overarching drug classes are presented in order of descending prevalence in 2011-2012.
Difference in prevalence represents the absolute increase or decrease in prevalence of use between 1999-2000 and 2011-2012.
Prevalence ratio represents the relative increase or decrease in prevalence of use between 1999-2000 and 2011-2012.
Excludes COX-2 inhibitors.
- No use
Data withheld due to relative standard error >30%. Results for a given survey cycle are not presented if the relative standard error (RSE=[SE of prevalence/prevalence]*100) exceeds 30%, consistent with NHANES analytic guidelines.
### eTable 5. Trends in Use of Prescription Drugs in the Prior 30 Days Among US Adults by Race/Ethnicity—1999-2012

<table>
<thead>
<tr>
<th></th>
<th>Non-Hispanic White</th>
<th>Non-Hispanic Black</th>
<th>Mexican-American</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1999-2000 (n=2,210)</td>
<td>2011-2012 (n=2,040)</td>
<td>2011-2012 (n=939)</td>
</tr>
<tr>
<td>Antihypertensive agents</td>
<td>p-trend</td>
<td>Difference in Prevalence(^a)% (95% CI)</td>
<td>Prevalence Ratio(95% CI)</td>
</tr>
<tr>
<td>Any prescription</td>
<td>&lt;0.001</td>
<td>1.1 (0.9, 1.3)</td>
<td>1.2 (1.1, 1.3)</td>
</tr>
<tr>
<td>≥5 prescriptions</td>
<td>&lt;0.001</td>
<td>1.6 (1.5, 1.7)</td>
<td>1.7 (1.6, 1.8)</td>
</tr>
<tr>
<td>Angiotensin II inhibitors</td>
<td>&lt;0.001</td>
<td>2.3 (2.0, 2.6)</td>
<td>2.6 (2.3, 2.9)</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>&lt;0.001</td>
<td>1.5 (1.4, 1.6)</td>
<td>1.7 (1.6, 1.8)</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>&lt;0.001</td>
<td>2.6 (2.3, 2.9)</td>
<td>2.9 (2.7, 3.2)</td>
</tr>
<tr>
<td>Calcium-channel blockers</td>
<td>&lt;0.001</td>
<td>0.5 (0.4, 0.6)</td>
<td>0.6 (0.5, 0.8)</td>
</tr>
<tr>
<td>Potassium-sparing agents</td>
<td>&lt;0.001</td>
<td>8.9 (7.4, 10.4)</td>
<td>9.8 (8.5, 11.3)</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>&lt;0.001</td>
<td>0.6 (0.4, 0.8)</td>
<td>0.7 (0.5, 0.9)</td>
</tr>
<tr>
<td>Antihyperlipidemic agents</td>
<td>&lt;0.001</td>
<td>0.8 (0.6, 1.0)</td>
<td>0.9 (0.7, 1.1)</td>
</tr>
<tr>
<td>Statins</td>
<td>0.05</td>
<td>2.8 (2.4, 3.2)</td>
<td>3.1 (2.7, 3.5)</td>
</tr>
</tbody>
</table>

\(^a\) Prevalence \(\% (95\% CI)\)
<table>
<thead>
<tr>
<th>Non-Hispanic White</th>
<th>Non-Hispanic Black</th>
<th>Mexican-American</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prescription proton-pump inhibitors</strong></td>
<td><strong>Hypertension</strong></td>
<td><strong>Hypertension</strong></td>
</tr>
<tr>
<td>4.6</td>
<td>8.3 (4.8, 13)</td>
<td>4.3 (2.5, 7.2)</td>
</tr>
<tr>
<td>6.1</td>
<td>8.1 (6.8, 9.4)</td>
<td>6.9 (5.8, 8.2)</td>
</tr>
<tr>
<td>2.7</td>
<td>4.0 (2.8, 5.5)</td>
<td>1.5 (1.1, 2.0)</td>
</tr>
<tr>
<td>1.5 (1.0, 2.3)</td>
<td>1.9 (1.0, 3.5)</td>
<td>1.4 (0.9, 2.4)</td>
</tr>
<tr>
<td><strong>Anticoagulants</strong></td>
<td><strong>Hypertension</strong></td>
<td><strong>Hypertension</strong></td>
</tr>
<tr>
<td>2.6</td>
<td>3.5 (2.4, 4.8)</td>
<td>2.0 (1.3, 3.2)</td>
</tr>
<tr>
<td>1.6</td>
<td>2.4 (1.2, 2.9)</td>
<td>1.9 (1.0, 3.4)</td>
</tr>
<tr>
<td>1.3</td>
<td>1.7 (1.2, 2.0)</td>
<td>1.4 (0.8, 2.4)</td>
</tr>
<tr>
<td><strong>Antihypertensives</strong></td>
<td><strong>Hypertension</strong></td>
<td><strong>Hypertension</strong></td>
</tr>
<tr>
<td>2.7</td>
<td>4.3 (2.6, 5.9)</td>
<td>2.0 (1.2, 3.2)</td>
</tr>
<tr>
<td>1.0</td>
<td>1.7 (1.3, 2.1)</td>
<td>1.4 (0.8, 2.4)</td>
</tr>
<tr>
<td>1.3</td>
<td>1.9 (1.2, 2.6)</td>
<td>1.4 (0.9, 2.4)</td>
</tr>
<tr>
<td><strong>Insulin</strong></td>
<td><strong>Hypertension</strong></td>
<td><strong>Hypertension</strong></td>
</tr>
<tr>
<td>1.9</td>
<td>3.8 (2.2, 5.8)</td>
<td>2.5 (1.5, 4.0)</td>
</tr>
<tr>
<td>1.4</td>
<td>2.6 (1.6, 3.4)</td>
<td>1.8 (1.1, 3.0)</td>
</tr>
<tr>
<td>1.1</td>
<td>1.7 (1.1, 2.4)</td>
<td>1.5 (0.9, 2.5)</td>
</tr>
<tr>
<td><strong>Benzodiazepines</strong></td>
<td><strong>Hypertension</strong></td>
<td><strong>Hypertension</strong></td>
</tr>
<tr>
<td>1.6</td>
<td>3.0 (2.0, 4.4)</td>
<td>1.5 (1.0, 2.2)</td>
</tr>
<tr>
<td>1.0</td>
<td>1.5 (1.1, 2.0)</td>
<td>1.1 (0.7, 1.7)</td>
</tr>
<tr>
<td>0.9</td>
<td>1.4 (0.9, 2.2)</td>
<td>1.1 (0.7, 1.7)</td>
</tr>
<tr>
<td><strong>Bronchodilators</strong></td>
<td><strong>Hypertension</strong></td>
<td><strong>Hypertension</strong></td>
</tr>
<tr>
<td>1.5</td>
<td>2.9 (1.9, 4.0)</td>
<td>1.9 (1.2, 3.2)</td>
</tr>
<tr>
<td>1.0</td>
<td>1.6 (1.1, 2.3)</td>
<td>1.2 (0.8, 1.8)</td>
</tr>
<tr>
<td>0.9</td>
<td>1.4 (0.9, 2.2)</td>
<td>1.1 (0.7, 1.7)</td>
</tr>
<tr>
<td><strong>Antidepressants</strong></td>
<td><strong>Hypertension</strong></td>
<td><strong>Hypertension</strong></td>
</tr>
<tr>
<td>1.4</td>
<td>2.9 (1.9, 4.0)</td>
<td>1.9 (1.2, 3.2)</td>
</tr>
<tr>
<td>1.0</td>
<td>1.6 (1.1, 2.3)</td>
<td>1.2 (0.8, 1.8)</td>
</tr>
<tr>
<td>0.9</td>
<td>1.4 (0.9, 2.2)</td>
<td>1.1 (0.7, 1.7)</td>
</tr>
<tr>
<td><strong>Muscle relaxants</strong></td>
<td><strong>Hypertension</strong></td>
<td><strong>Hypertension</strong></td>
</tr>
<tr>
<td>0.6</td>
<td>1.1 (0.7, 1.5)</td>
<td>0.8 (0.5, 1.2)</td>
</tr>
<tr>
<td>0.4</td>
<td>0.6 (0.4, 0.8)</td>
<td>0.4 (0.3, 0.6)</td>
</tr>
<tr>
<td>0.4</td>
<td>0.7 (0.5, 1.0)</td>
<td>0.5 (0.3, 0.8)</td>
</tr>
<tr>
<td><strong>Nasal medications</strong></td>
<td><strong>Hypertension</strong></td>
<td><strong>Hypertension</strong></td>
</tr>
<tr>
<td>0.6</td>
<td>1.1 (0.7, 1.5)</td>
<td>0.8 (0.5, 1.2)</td>
</tr>
<tr>
<td>0.4</td>
<td>0.6 (0.4, 0.8)</td>
<td>0.4 (0.3, 0.6)</td>
</tr>
<tr>
<td>0.4</td>
<td>0.7 (0.5, 1.0)</td>
<td>0.5 (0.3, 0.8)</td>
</tr>
<tr>
<td>Drug Class</td>
<td>Non-Hispanic White</td>
<td>Non-Hispanic Black</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>--------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td></td>
<td>1999-2000 (n=2,210)</td>
<td>2011-2012 (n=2,040)</td>
</tr>
<tr>
<td></td>
<td>1999-2000 (n=904)</td>
<td>2011-2012 (n=1,455)</td>
</tr>
<tr>
<td></td>
<td>1999-2000 (n=1,280)</td>
<td>2011-2012 (n=539)</td>
</tr>
<tr>
<td></td>
<td>Difference in Prevalence (%)</td>
<td>Prevalence Ratio (95% CI)</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>1.2</td>
<td>1.7 (1.2, 2.5)</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>2.5</td>
<td>1.7 (1.2, 2.3)</td>
</tr>
<tr>
<td>Prescription ophthalmic preparations</td>
<td>1.1</td>
<td>1.7 (1.1, 2.5)</td>
</tr>
</tbody>
</table>

**ABBREVIATION:** ACE (Angiotensin Converting Enzyme); NSAID (Non-Steroidal Anti-Inflammatory Drug); SSNRI (Selective Serotonin–Norepinephrine Reuptake Inhibitor); SSRI (Selective Serotonin Reuptake Inhibitor)

- All data are weighted to be nationally representative.
- Overarching drug classes are presented in order of descending prevalence in 2011-2012.
- Difference in prevalence represents the absolute increase or decrease in prevalence of use between 1999-2000 and 2011-2012.
- Prevalence ratio represents the relative increase or decrease in prevalence of use between 1999-2000 and 2011-2012.
- Excludes COX-2 inhibitors.
- Analyses limited to women.
- No use
- Data withheld due to relative standard error >30%; results for a given survey cycle are not presented if the relative standard error (RSE=[SE of prevalence/prevalence]*100) exceeds 30%, consistent with NHANES analytic guidelines.© 2015 American Medical Association. All rights reserved.
### eTable 6. Age-Adjusted Trends in Use of Selected Prescription Drugs in the Prior 30 Days Among US Adults by Race/Ethnicity—1999-2012\(^{a,b,c}\)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Non-Hispanic White</th>
<th>Non-Hispanic Black</th>
<th>Mexican-American</th>
<th>P-trend</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Any prescription</strong></td>
<td>55</td>
<td>63 (60.85)</td>
<td>-0.01</td>
<td>.001</td>
</tr>
<tr>
<td><strong>25 prescriptions</strong></td>
<td>9.2</td>
<td>15 (13.17)</td>
<td>-0.01</td>
<td>9.7</td>
</tr>
<tr>
<td><strong>Antihypertensive agents</strong></td>
<td>21</td>
<td>25 (24.77)</td>
<td>-0.01</td>
<td>7.9</td>
</tr>
<tr>
<td><strong>Antithrombotic agents</strong></td>
<td>9.0</td>
<td>17 (15.19)</td>
<td>-0.01</td>
<td>7.9</td>
</tr>
<tr>
<td><strong>Antidepressants</strong></td>
<td>8.1</td>
<td>16 (14.19)</td>
<td>-0.01</td>
<td>8.3</td>
</tr>
<tr>
<td><strong>Prescription analgesics</strong></td>
<td>12</td>
<td>12 (9.05)</td>
<td>0.089</td>
<td>3.5</td>
</tr>
<tr>
<td><strong>Sex hormones</strong></td>
<td>24</td>
<td>15 (11.18)</td>
<td>-0.01</td>
<td>9.8</td>
</tr>
<tr>
<td><strong>Antidiabetic agents</strong></td>
<td>3.7</td>
<td>6.3 (5.3, 7.4)</td>
<td>-0.01</td>
<td>3.8</td>
</tr>
<tr>
<td><strong>Prescription proton-pump inhibitors</strong></td>
<td>4.6</td>
<td>7.6 (6.0, 10)</td>
<td>0.038</td>
<td>3.7</td>
</tr>
<tr>
<td><strong>Thyroid hormones</strong></td>
<td>6.0</td>
<td>7.2 (6.1, 8.5)</td>
<td>0.028</td>
<td>1.2</td>
</tr>
<tr>
<td><strong>Hypnotics</strong></td>
<td>4.6</td>
<td>7.2 (5.7, 9.0)</td>
<td>0.001</td>
<td>2.6</td>
</tr>
<tr>
<td><strong>Anticonvulsants</strong></td>
<td>2.5</td>
<td>6.2 (5.1, 7.6)</td>
<td>-0.01</td>
<td>2.2</td>
</tr>
<tr>
<td><strong>Bronchodilators</strong></td>
<td>3.3</td>
<td>5.5 (4.2, 7.2)</td>
<td>0.001</td>
<td>2.2</td>
</tr>
<tr>
<td><strong>Antibiotics</strong></td>
<td>5.9</td>
<td>5.0 (4.5, 5.5)</td>
<td>0.002</td>
<td>-0.9</td>
</tr>
<tr>
<td><strong>Antihypertensive agents</strong></td>
<td>5.6</td>
<td>2.9 (2.2, 4.0)</td>
<td>-0.01</td>
<td>-2.6</td>
</tr>
<tr>
<td><strong>Coagulation modifiers</strong></td>
<td>2.5</td>
<td>3.6 (3.1, 4.1)</td>
<td>-0.01</td>
<td>1.1</td>
</tr>
<tr>
<td><strong>Muscle relaxants</strong></td>
<td>1.4</td>
<td>2.8 (1.7, 4.4)</td>
<td>0.019</td>
<td>1.4</td>
</tr>
<tr>
<td><strong>H2 antagonists</strong></td>
<td>2.1</td>
<td>2.7 (1.9, 3.7)</td>
<td>0.15</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>Prescription antihistamines</strong></td>
<td>4.1</td>
<td>2.3 (1.7, 3.2)</td>
<td>-0.01</td>
<td>-1.8</td>
</tr>
<tr>
<td><strong>Antiemetic/Antivertigo agents</strong></td>
<td>2.1</td>
<td>1.9 (1.5, 3.0)</td>
<td>0.82</td>
<td>0.2</td>
</tr>
<tr>
<td><strong>Antipsychotics</strong></td>
<td>1.3</td>
<td>1.8 (1.2, 2.6)</td>
<td>0.20</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>Glucocorticoids</strong></td>
<td>2.5</td>
<td>1.5 (1.1, 2.1)</td>
<td>0.002</td>
<td>-1.0</td>
</tr>
</tbody>
</table>

\(^a\) All data are weighted to be nationally representative.

\(^b\) Overarching drug classes are presented in order of descending prevalence in 2011-2012.

\(^c\) Age-adjusted using standardization and the 2000 US Standard Population (based on 5-year age groups, up to 80y+).

\(^d\) Difference in prevalence represents the absolute increase or decrease in prevalence of use between 1999-2000 and 2011-2012.

\(^e\) Ratio of prevalence represents the relative increase or decrease in prevalence of use between 1999-2000 and 2011-2012.

\(^f\) Analyses limited to women.

\(^g\) All data are weighted to be nationally representative.

\(^h\) Data withheld due to relative standard error >30%; results for a given survey cycle are not presented if the relative standard error (RSE=[SE of prevalence/prevalence]*100) exceeds 30%, consistent with NHANES analytic guidelines.
Table 7. Age and Insurance-Adjusted Trends in Use of Any Prescription Drugs and Polypharmacy by Race/Ethnicity—1999-2012<sup>a,b</sup>

<table>
<thead>
<tr>
<th></th>
<th>Non-Hispanic White</th>
<th>Non-Hispanic Black</th>
<th>Mexican-American</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1999-2000 (n=2,158)</td>
<td>2011-2012 (n=2,039)</td>
<td>1999-2000 (n=1,247)</td>
</tr>
<tr>
<td>Any prescription</td>
<td>53 (58, 62)</td>
<td>60 (56, 64)</td>
<td>42 (40, 43)</td>
</tr>
<tr>
<td></td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td></td>
<td>(n=881)</td>
<td>(n=1,453)</td>
<td>(n=1,247)</td>
</tr>
<tr>
<td></td>
<td>p-trend</td>
<td>p-trend</td>
<td>p-trend</td>
</tr>
<tr>
<td>Difference in Prevalence&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.8 (3.6, 10)</td>
<td>11 (1.0, 12)</td>
<td>2.1 (-1.3, 5.6)</td>
</tr>
<tr>
<td>Ratio of Prevalence&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.1 (1.0, 1.2)</td>
<td>1.04 (0.97, 1.1)</td>
<td>1.3 (1.0, 1.6)</td>
</tr>
<tr>
<td>≥5 prescriptions</td>
<td>8.6 (7.8, 9.3)</td>
<td>11 (11, 15)</td>
<td>6.9 (6.2, 7.7)</td>
</tr>
<tr>
<td></td>
<td>14 (12, 15)</td>
<td>13 (11, 15)</td>
<td>12 (8, 16)</td>
</tr>
<tr>
<td></td>
<td>%</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td></td>
<td>(n=538)</td>
<td>(n=538)</td>
<td>(n=538)</td>
</tr>
<tr>
<td>p-trend</td>
<td>&lt;.001</td>
<td>.11</td>
<td>.013</td>
</tr>
<tr>
<td>Ratio of Prevalence&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.6 (1.3, 1.8)</td>
<td>3.0 (0.3, 5.7)</td>
<td>1.3 (1.0, 1.6)</td>
</tr>
<tr>
<td></td>
<td>(95% CI)</td>
<td>(95% CI)</td>
<td>(95% CI)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Age and insurance-adjusted using standardization by age group (5-year age groups, up to 80+y) and insurance status (no insurance, government insurance only, private insurance only and both government and private insurance) was conducted using the 1999-2000 cycle of NHANES as the standard. This cycle was used as the reference as it most closely resembles the 2000 Standard Population, and allows for comparison to the age-adjusted analysis.

<sup>b</sup> All data are weighted to be nationally representative.

<sup>c</sup> Difference in prevalence represents the absolute increase or decrease in prevalence of use between 1999-2000 and 2011-2012.

<sup>d</sup> Prevalence ratio represents the relative increase or decrease in prevalence of use between 1999-2000 and 2011-2012.
<table>
<thead>
<tr>
<th>eTable 8. Trends in the 25 Most Commonly Used Individual Prescription Medications in the Prior 30 Days—2011-2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>%</td>
</tr>
<tr>
<td><strong>Simvastatin</strong></td>
</tr>
<tr>
<td><strong>Lisinopril</strong></td>
</tr>
<tr>
<td><strong>Levothyroxine</strong></td>
</tr>
<tr>
<td><strong>Metoprolol</strong></td>
</tr>
<tr>
<td><strong>Metformin</strong></td>
</tr>
<tr>
<td><strong>Hydrochlorothiazide</strong></td>
</tr>
<tr>
<td><strong>Omeprazole</strong></td>
</tr>
<tr>
<td><strong>Amlodipine</strong></td>
</tr>
<tr>
<td><strong>Atorvastatin</strong></td>
</tr>
<tr>
<td><strong>Albuterol</strong></td>
</tr>
<tr>
<td><strong>Acetaminophen &amp; hydrocodone</strong></td>
</tr>
<tr>
<td><strong>Citalopram</strong></td>
</tr>
<tr>
<td><strong>Sertraline</strong></td>
</tr>
<tr>
<td><strong>Furosemide</strong></td>
</tr>
<tr>
<td><strong>Potassium chloride</strong></td>
</tr>
<tr>
<td><strong>Atenolol</strong></td>
</tr>
<tr>
<td><strong>Losartan</strong></td>
</tr>
<tr>
<td><strong>Pravastatin</strong></td>
</tr>
<tr>
<td><strong>Ranitidine</strong></td>
</tr>
<tr>
<td><strong>Gabapentin</strong></td>
</tr>
<tr>
<td><strong>Fluticasone nasal</strong></td>
</tr>
<tr>
<td><strong>Zolpidem</strong></td>
</tr>
<tr>
<td><strong>Fluoxetine</strong></td>
</tr>
<tr>
<td><strong>Esomeprazole</strong></td>
</tr>
<tr>
<td><strong>Hydrochlorothiazide &amp; lisinopril</strong></td>
</tr>
</tbody>
</table>

*a* Difference in prevalence represents the absolute increase or decrease in prevalence of use between 1999-2000 and 2011-2012.

*b* Prevalence ratio represents the relative increase or decrease in prevalence of use between 1999-2000 and 2011-2012.

- No use

¶ Data withheld due to relative standard error >30%; results for a given survey cycle are not presented if the relative standard error (RSE=[SE of prevalence/prevalence]*100) exceeds 30%, as denoted by ¶, consistent with NHANES analytic guidelines.23

© 2015 American Medical Association. All rights reserved.